ReviewOncolytic viruses in radiation oncology
Section snippets
Principles of viral therapies in oncology
Viruses have been widely studied as vectors for therapeutic genes. Gene therapy consists of the introduction of genetic material into cells for a therapeutic purpose. Recombinant viruses have been shown to be an efficient means of achieving gene transfer both in vitro and in vivo. Many viruses, such as adenovirus, adeno-associated virus (AAV), retrovirus, lentivirus, herpes simplex virus (HSV), poxvirus, measles virus, simian virus 40 recombinant (SV40r) and vesicular stomatitis virus have been
Antitumour activity
Antitumour activities in vitro and in vivo of various viral agents in combination with EBRT have been investigated in a variety of tumour models. The combination of viruses and EBRT has shown additive or synergistic therapeutic effects in vitro and in subcutaneous prostate, head and neck, lung, colon, thyroid and cholangiocarcinomas, as well as melanoma and malignant glioma [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25].
In
DNA damage signalling
Ionizing radiation produces a wide variety of lesions in DNA, including base damage, single- and double-strand breaks (DSB) and DNA–DNA or DNA–protein crosslinks [54]. These lesions can be topographically grouped and clustered within the same region of DNA to comprise so-called “complex damage” [55]. DSBs breaks play an important role in cell death induced by radiation. Two major mechanisms of repair of DSBs have been described: the non-homologous end-joining (NHEJ) mechanisms and homologous
Conclusion
Viral therapies are unlikely to be used widely in the clinic as single agents. However, it is increasingly recognized that combining viral therapies with EBRT represents a promising approach. Preclinical studies support this strategy showing that combination regimens yield increased antitumour effects as compared with single treatment modalities. A number of potential mechanisms of interaction between viruses and radiation have been described. Radiation can increase viral uptake, gene
Authors’ declaration of personal interests
K.J. Harrington has received unrestricted educational grants in support of laboratory and clinical research from Oncolytics Biotech Inc. and Genelux GmbH.
Acknowledgements
Y. Touchefeu has received a doctoral research grant from the Institut National du Cancer and a research grant from the Société Nationale Française de Gastro-Entérologie (Robert Tournut grant). Part of this work was undertaken in The Royal Marsden NHS Foundation Trust who received a proportion of its funding from the NHS Executive; the views expressed in this publication are those of the authors and not necessarily those of the NHS Executive. This work was supported by The Institute of Cancer
References (105)
- et al.
Intelligent design: combination therapy with oncolytic viruses
Mol Ther
(2010) - et al.
Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma
Radiother Oncol
(2008) - et al.
Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model
Int J Radiat Oncol Biol Phys
(2002) - et al.
Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair
Mol Ther
(2010) - et al.
Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer
Neoplasia
(2001) - et al.
Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck
Eur J Cancer
(2005) - et al.
Response to multiple radiation doses of human colorectal carcinoma cells infected with recombinant adenovirus containing dominant-negative Ku70 fragment
Int J Radiat Oncol Biol Phys
(2010) - et al.
Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts
Mol Ther
(2003) - et al.
Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer
Mol Ther
(2007) - et al.
AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study
Mol Ther
(2004)
Phase I–II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data
Int J Radiat Oncol Biol Phys
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Lancet Oncol
Dose-effect relation in stereotactic radiotherapy for brain metastases. A systematic review
Radiother Oncol
A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer
Radiother Oncol
Dose–volume effects for normal tissues in external radiotherapy: pelvis
Radiother Oncol
Role of H2AX in DNA damage response and human cancers
Mutat Res
New insights on cell death from radiation exposure
Lancet Oncol
Human Rad50/Mre11 is a flexible complex that can tether DNA ends
Mol Cell
Choreography of the DNA damage response: spatiotemporal relationships among checkpoint and repair proteins
Cell
The mammalian Mre11-Rad50-nbs1 protein complex: integration of functions in the cellular DNA-damage response
Am J Hum Genet
Crosstalk between histone modifications during the DNA damage response
Trends Cell Biol
Impaired DNA damage response – an Achilles’ heel sensitizing cancer to chemotherapy and radiotherapy
Eur J Pharmacol
Cohesin and DNA damage repair
Exp Cell Res
Coordination between cell cycle progression and cell fate decision by the p53 and E2F1 pathways in response to DNA damage
J Biol Chem
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents
J Biol Chem
The mechanism of human nonhomologous DNA end joining
J Biol Chem
Viral manipulation of DNA repair and cell cycle checkpoints
DNA Repair (Amst)
HTLV-1 Tax oncoprotein subverts the cellular DNA damage response via binding to DNA-dependent protein kinase
J Biol Chem
HIV-1 Tat depresses DNA-PK(CS) expression and DNA repair, and sensitizes cells to ionizing radiation
Int J Radiat Oncol Biol Phys
Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation
Virology
The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner
J Biol Chem
Gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair
Mol Cell
The adenoviral E4orf6 protein induces atypical apoptosis in response to DNA damage
J Biol Chem
Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology
Aliment Pharmacol Ther
Gene therapy progress and prospects cancer: oncolytic viruses
Gene Ther
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Nat Rev Cancer
Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer
Ann Thorac Surg
Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors
Gene Ther
CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity
Cancer Res
Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity
Cancer Gene Ther
Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer
Cancer Gene Ther
Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts
Br J Cancer
Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy
Cancer Gene Ther
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy
Cancer Res
Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme
Clin Cancer Res
Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer
Int J Radiat Biol
Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells
Cancer Res
ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells
J Clin Endocrinol Metab
In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
Cancer Res
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy
Clin Cancer Res
Cited by (52)
A promising future in cancer immunotherapy: Oncolytic viruses
2023, European Journal of PharmacologyCurrent landscape and perspective of oncolytic viruses and their combination therapies
2022, Translational OncologyCitation Excerpt :Both radiotherapy and oncolytic virotherapy can greatly break TME in solid tumors. There is evidence that radiotherapy can increase adenovirus infectivity by upregulating CAR expression in colorectal (HCT116) and head and neck (SIHN-5B) cancer cells [83]. Once OV infects cancer cells, viral proteins interact with cellular proteins that are involved in response of the radiation-induced DNA damage and modulate the activity of signaling pathways [84].
Modeling dynamics of cancer radiovirotherapy
2020, Journal of Theoretical BiologyOncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma
2019, EBioMedicineCitation Excerpt :To our knowledge, the combination of localised oncolytic virus therapy and radiation has not been evaluated for efficacy in animal models in combination with checkpoint inhibitors. Viruses are well known radiosensitisers, [36] and both oncolytic viruses and RT have the potential to activate the immune system and work synergistically with checkpoint blockade. Here we have selected a well-characterised oncolytic virus to evaluate this potential combination.
Science in Focus – Oncolytic Viruses: New Multifunctional Immunotherapeutics
2016, Clinical Oncology